During the recent J.P. Morgan 44th Annual Healthcare Conference in San Francisco, Jonathan Grinstein, PhD, North American editor of Inside Precision Medicine, and Alex Philippidis, senior business editor of IPM’s sister publication Genetic Engineering and Biotechnology News (GEN) took a break from interviewing CEOs, attending corporate presentations, and walking up the city’s famed hills to share some insights about their week at the event—and more broadly, where biopharma now stands and is expected to go in 2026.
